

Complex PCI: Left Main and Bifurcation


New data from RCT and registry

Y. Louvard, ICPS, Massy, Générale de Santé-Ramsay, France

TCTAP 2016, Seoul, Korea

Predictors of SB occlusion after cross-over stenting ?

An Angiographic Tool for Risk Prediction of Side Branch Occlusion in Coronary Bifurcation Intervention: The RESOLVE Score System



An Angiographic Tool for Risk Prediction of Side Branch Occlusion in Coronary Bifurcation Intervention: The RESOLVE Score System

Scores Attributed to Each Variable

Risk Factor	Level	Point
Plaque distribution	At the opposite side of SB	0
	At the same side of SB	1
MV TIMI flow grade before stenting	TIMI 3	0
	TIMI 2	6
	TIMI 1	11
	TIMI 0	17
Pre-procedural diameter stenosis of bifurcation core (%)	<50	0
	50-<70	2
	≥70	3
Bifurcation angle (°)	<70	0
	70-<90	4
	≥90	6
Diameter ratio between MV/SB	<1.0	0
	1.0-<1.5	2
	1.5-<2.0	6
	≥2.0	9
Diameter stenosis of SB before MV stenting (%)	<50	0
	50-<70	4
	70-<90	6
	≥90	7

- Acute bifurcation angle = carena shift no occlusion (Vassiliev)
- Carena shift \neq SB stenosis (Koo)
- Plaque shift from proximal main is a factor of occlusion (Hahn)
- Angle not a predictor of SB occlusion (Hahn)
- Wide bifurcation angle = predictor of occlusion (plaque shifting, no carena shift)(Dou)

1 vs 2 stents for bifurcation stenting when the SB is big and the SB stenosis is long ?



**Randomized comparison of provisional side branch stenting versus
a two-stent strategy for treatment of
true coronary bifurcation lesions involving a large side branch.**

Two-year results in the Nordic-Baltic Bifurcation Study IV


Indulis Kumsars, **Niels R. Holm**, Matti Niemelä, Andrejs Erglis, Kari Kervinen, Evald H. Christiansen, Michael Maeng, Andis Dombrovskis, Vytautas Abraitis, Aleksandras Kibarskis, Terje K. Steigen, Thor Trovik, Gustavs Latkovskis, Dace Sondore, Inga Narbute, Christian Juhl Terkelsen, Markku Eskola, Hannu Romppanen, Lisette Okkels Jensen, Mika Laine, Tuija Vasankari, Pål Gunnes, Lasse Hebsgaard, Ole Frobert, Fredrik Calais, Jens Aaroe, Juha Hartikainen, Svend Eggert Jensen, Jan Ravkilde, Thomas Engstrøm, Leif Thuesen, Jens F. Lassen

For the Nordic-Baltic PCI Study Group



Nordic-Baltic Bifurcation Study IV

Two-year MACE



Number at risk	0	100	200	300	400	500	600	700
Two-stent tech.	228	221	221	214	212	211	209	206
Provisional tech.	218	209	208	196	194	192	189	187


MACE: cardiac death, non-procedural myocardial infarction, target lesion revascularization and definite stent thrombosis



The European Bifurcation Coronary study: a randomised comparison of provisional T-stenting versus a systematic **TWO** stent strategy in large calibre true bifurcations

David Hildick-Smith, Goran Stankovic, Manuel Pan, Philippe Brunel, Didier Carrie, Michael Maeng,
Mark Spence, Keith Oldroyd, Alaide Chieffo, Thomas Hovasse, Andreas Baumbach, Jens Lassen,
Thierry Lefevre and Yves Louvard *on behalf of the EBC TWO trial investigators*

The EBC two trial is an investigator-initiated trial made possible by unrestricted grants by

 *Europe and Pie Medical*




PRIMARY ENDPOINT

	Provisional T (n=103)	Culotte (n=97)
Death, MI, TVR at 12 months	8 (8%)	10 (10%)
Death	2 (2%)	1 (1%)
Myocardial infarction	5 (5%)	10 (10%)
NSTEMI	5	9
STEMI	0	1
<48H	4	10
TVR	3 (3%)	1 (1%)
Stent thrombosis	1 (1%)	3 (3%)
Definite / Probable	1	2
Possible	0	1


16% double stenting in Provisional

Randomized Comparisons Between Different Stenting Approaches for Bifurcation Coronary Lesions With or Without Side Branch Stenosis



Randomized Comparisons Between Different Stenting Approaches for Bifurcation Coronary Lesions With or Without Side Branch Stenosis

MACE in the PERFECT Studies



1 vs 2 stents for bifurcation stenting: long term outcome

Long term all-cause mortality in treatment of coronary bifurcation lesion

*Pooled Analysis of
The BBC ONE Study and The Nordic Bifurcation Study I*


Miles Behan, Niels R. Holm, Adam de Belder, Matti Niemela, Nick Curzen, Kari Kervinen, Andrejs Erglis, Indulis Kumsars, Keith G. Oldroyd, Paal Gunnes, Rodney H. Stables, Michael Maeng, Terje K. Steigen, Lisette Okkels Jensen, Leif Thuesen, Jens F. Lassen, David Hildick-Smith

**On behalf on the
British Bifurcation Coronary and Nordic PCI Study Groups**

9-Month Trial Endpoints


	Simple (n=457)	Complex (n=456)	P value
Composite (death/MI/TVR) n (%)	46 (10.1)	79 (17.3)	0.001
All cause death n (%)	5 (1.0)	5 (1.0)	0.99
MI total n (%)	22 (4.8)	56 (12.3)	<0.001
-Periprocedural MI n (%)	16 (3.5)	45 (9.9)	<0.001
-Subsequent MI n (%)	6 (1.3)	11 (2.4)	0.22
TVR total n (%)	26 (5.7)	33 (7.2)	0.34
-TVRCABG n (%)	2 (0.4)	13 (2.9)	0.004
-TVRCABG n (%)	2 (0.4)	13 (2.9)	0.004
ST n (%)	3 (0.7)	6 (1.3)	0.31

BBC-Nordic: 5-year total death




Kissing or not after single stenting ?

Long-term Clinical outcomes of final KB in coronary bifurcation lesions treated with the 1-stent : results from the COBIS II registry



Long-term Clinical outcomes of final KB in coronary bifurcation lesions treated with the 1-stent: results from the COBIS II registry

Unadjusted Kaplan-Meier Curves in FKB Versus Non-FKB Groups



(A) Kaplan-Meier curves for MACE in FKB versus non-FKB groups in **all patients**. (B) Kaplan-Meier curves for MACE in FKB versus non-FKB groups in **propensity-matched populations**.

Long-term Clinical outcomes of final KB in coronary bifurcation lesions treated with the 1-stent: results from the COBIS II registry


Clinical Outcomes in FKB Group Compared With Non-FKB Group in Propensity-Matched Population During FU Period

	FKB (n = 545)	Non-FKB (n = 545)	Unadjusted HR (95% CI)	p Value	Adjusted HR* (95% CI)	p Value
All-cause death	17 (3.1)	20 (3.7)	0.67 (0.30-1.48)	0.32	0.68 (0.28-1.63)	0.39
Cardiac death	3 (0.6)	8 (1.5)	0.43 (0.11-1.66)	0.22	0.50 (0.11-2.29)	0.37
MI	4 (0.7)	5 (0.9)	0.50 (0.09-2.73)	0.42	0.18 (0.01-20.36)	0.48
Stent thrombosis†	3 (0.6)	4 (0.7)	0.72 (0.16-3.23)	0.67	0.77 (0.17-3.45)	0.73
Target lesion revascularization	32 (5.9)	43 (7.9)	0.53 (0.30-0.94)	0.03	0.51 (0.28-0.91)	0.02
Main vessel	31 (5.7)	40 (7.3)	0.53 (0.30-0.96)	0.04	0.51 (0.28-0.93)	0.03
Side branch	12 (2.2)	18 (3.3)	0.57 (0.24-1.36)	0.21	0.57 (0.24-1.37)	0.21
Both vessels	23 (4.2)	38 (7.0)	0.47 (0.25-0.88)	0.02	0.47 (0.25-0.90)	0.02
MACE‡	37 (6.8)	53 (9.7)	0.54 (0.32-0.89)	0.02	0.50 (0.30-0.85)	0.01

*Adjusted covariates include hypertension, history of coronary artery bypass graft, and distal RD of SB.

Long-term Clinical outcomes of final KB in coronary bifurcation lesions treated with the 1-stent technique: results from the COBIS II registry


Comparative Unadjusted HR of MACE for Subgroups in Propensity-Matching Population



no significant interactions between the use of FKB and MACE among various subgroups in propensity-matching populations.






2nd 3rd generation stents ?

1st vs 2nd generation DES for treatment of bifurcations: 5-year FU of the LEADERS all-comers randomized trial




1st vs 2nd generation DES for treatment of bifurcations: 5-year FU of the LEADERS all-comers randomized trial

Cumulative event rates of patients with at least one bifurcation treated with SES and BES




1st vs 2nd generation DES for treatment of bifurcations: 5-year FU of the LEADERS all-comers randomized trial

Event rates beyond 1 year of patients with at least one bifurcation treated with SES vs BES



1st - and 2nd -Generation DES in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts




1st - and 2nd -Generation DES in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts

Angiographic and Procedural Characteristics

	First-Generation DES (n = 2,475)			Second-Generation DES (n = 687)		
	1-Stent (n = 1,802)	2-Stent (n = 673)	p Value	1-Stent (n = 409)	2-Stent (n = 278)	p Value
Stent type			<0.001			<0.001
SES	992 (55.0)	422 (62.7)		–	–	
PES	614 (34.1)	208 (30.9)		–	–	
ZES-Splint	194 (10.8)	41 (6.1)		–	–	
EES	–	–		356 (87.0)	120 (43.2)	
ZES-Resolute	–	–		53 (13.0)	158 (56.8)	
Others	2 (0.1)	2 (0.3)		–	–	
Stenting techniques						NA
1-stent technique	1,802 (100.0)	–		409 (100.0)	–	
2-stent technique	–	673 (100.0)		–	278 (100.0)	
T-stenting or TAP	–	245 (36.4)		–	147 (52.9)	
Crush	–	323 (48.0)		–	98 (35.2)	
Kissing or V-stenting	–	87 (12.9)		–	14 (5.0)	
Culottes	–	15 (2.2)		–	16 (5.8)	
Others	–	3 (0.4)		–	3 (1.1)	


1st - and 2nd -Generation DES in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts

(A to C) Individual components of target lesion failure in 1st-generation DES. (D to F) Individual components of target lesion failure in 2nd generation DES



Prospective Multicentre Clinical Performance Evaluation of 2nd - 3rd Generation ZES to Treat Patients With Bifurcated Coronary Lesions

MACE-free survival according to implantation of a single or double stent




Does the technique still matter for bifurcation stenting with 2nd and 3rd generation DES: YES !

Which double stenting technique ?

Randomized Comparison of the Crush Versus the Culotte Stenting for Coronary Artery Bifurcation Lesions

Major adverse cardiac event-free survival rate at 12 months



*Original Colombo
crush*

*Original Chevalier
culotte (main first)*

Randomized Comparison of the Crush Versus the Culotte Stenting for Coronary Artery Bifurcation Lesions

Individual endpoints after 12 months in crush group and culotte group

Items	Crush group (n = 150)	Culotte group (n = 150)	P
Total death, n (%)	2 (1.3)	1 (0.7)	0.624
Cardiac death, n (%)	2 (1.3)	1 (0.7)	0.624
Myocardial infarction, n (%)	7 (4.7)	3 (2.0)	0.335
Stent thrombosis, n (%)	4 (2.7)	2 (1.3)	0.684
Target lesion revascularization, n (%)	8 (5.3)	6 (4.0)	0.584
Target vessel revascularization, n (%)	9 (6.0)	7 (4.7)	0.607
Index lesion restenosis, n (%)	19 (12.7)	9 (6.0)	0.047


Original Colombo
crush

Original Chevalier
culotte (main first)

DK crush (Chen) > Culotte (Nordic 2) > Classic crush (Zheng) ?

LM: CABG or Stent ?


Randomized Trial of Stents vs Bypass Surgery for LMCA Disease: 5-Year Outcomes of the PRECOMBAT Study



Randomized Trial of Stents vs Bypass Surgery for LMCA Disease: 5-Year Outcomes of the PRECOMBAT Study


Stenting vs CABG for Left Main Stenosis: Cumulative Event Curves of the Primary Endpoint and the Major Secondary Endpoint at the 5-Year FU

Composite of death from any cause, MI, stroke, or ischemia-driven TVR



Patients at Risk						
PCI	300	272	261	252	246	231
CABG	300	279	274	267	256	235

Composite of death of any cause, MI, or stroke







Patients at Risk						
PCI	300	288	284	277	270	256
CABG	300	287	284	277	268	247

waiting for EXCEL and NOBLE

Provisional vs. two-stent technique for ULM CAD after 10 years FU: A propensity matched analysis

Provisional vs. 2 stent technique after 10 year and 1 year FU before and after propensity score matching (n= 285)



* p < 0.05

waiting for **EBC main** (1 vs 2 stents for distal LM stenting)